Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADPT vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–4 Matrix Metrics)

ADPT Overall Winner 6-Pillar Tally: ADPT 4 – 2 PVLA Matrix Metrics: ADPT 4 – 4 PVLA

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $28.00 (N/M Forward P/E, -16.2% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. 0.0% operating margin) and revenue trajectory (-10.7% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADPT vs PVLA
ADPT NASDAQ Head-to-Head Winner
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.00
-3.58% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.75β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $27.26 · SMA50: $26.98
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42

6-Pillar Scorecard Institutional Category Breakdown (ADPT 4 – 2 PVLA)

Columns: Metric · ADPT · PVLA
1. Valuation Multiples ADPT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 16.8x N/M
2. Growth & Scale PVLA
Revenue Growth (YoY) -10.7% +0.0%
Earnings Growth (YoY) -70.1% +0.0%
TTM Revenue (USD) $298M N/A
Market Cap $4.7B $2.2B
3. Profitability & Quality PVLA
Gross Margin 46.2% N/A
Operating Margin -16.2% 0.0%
Net Profit Margin -23.7% 0.0%
Return on Equity (ROE) -36.4% -63.4%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$8.8M -$43M
Cash Flow Margin -3.0% N/A
Net Cash / Leverage $333M Net Debt (2.32x D/E) $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 74.2% (32nd %ile) 47.9% (2nd %ile)
Put/Call OI Skew N/A 3.82x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity 62.4% of Rev ($186M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADPT (4) vs PVLA (4)
Institutional Metric ADPT PVLA Criterion Row Edge
Market Capitalization
Scale
$4.7B $2.2B Larger Scale ADPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-10.7% +0.0% Higher Growth PVLA
Operating Margin (TTM)
Profitability
-16.2% 0.0% Higher Margin PVLA
Net Profit Margin
Profitability
-23.7% 0.0% Higher Margin PVLA
Return on Equity (ROE)
Capital Efficiency
-36.4% -63.4% Higher ROE ADPT
52-Week Range Position
Momentum
79% ($12–$32) 68% ($72–$180) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.75β · 60% Vol 1.66β · 75% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 48.2 / 100 (HOLD) Higher Composite PVLA
Trailing 12M Revenue (USD)
Operating Scale
$298M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M ($333M Net Debt (2.32x D/E)) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +3.99 pp
ADPT: +16.57% · PVLA: +20.56%
3M Horizon ADPT +17.59 pp
ADPT: +14.01% · PVLA: -3.58%
6M Horizon ADPT +82.24 pp
ADPT: +120.3% · PVLA: +38.06%
1Y Horizon ADPT +17.86 pp
ADPT: +98.02% · PVLA: +80.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ADPT Revenue PVLA Revenue ADPT Op. Margin PVLA Op. Margin Margin Leader
FY2018 $60M $30M -89.4% -113.1% ADPT
FY2019 $90M $40M -92.1% -62.2% PVLA
FY2020 $100M $30M -155.3% -115.7% PVLA
FY2021 $150M $30M -135.4% -165.0% ADPT
FY2022 $190M $30M -108.0% -167.8% ADPT
FY2023 $170M $40M -133.3% -27.7% PVLA
FY2024 $180M N/A -90.8% N/A ADPT
FY2025 $280M N/A -20.6% N/A ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 74.2%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADPT vs PVLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $28.00 (N/M Forward P/E, -16.2% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. 0.0% operating margin) and revenue trajectory (-10.7% vs. +0.0% YoY).

PVLA leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ADPT cumulative revenue shifted +366.7% while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

ADPT screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (-3.0% FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ADPT carries 74.2% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.75β · 60% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.